- Patients must have met the inclusion criteria for Study 1008-157, have received
double-blind study medication, and wish to receive open-label pregabalin
- Have the diagnosis of epilepsy with partial seizures and have a minimum of 4 partial
seizures during the 6 weeks prior to screening
- Be currently taking 1 to 3 AEDs.
- Have a treatable cause of seizures
- Experienced a serious adverse event during Study 1008-157 which was determined to be
possibly related to study medication